TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05646862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpelisib
Description: Alpelisib will be administered to participants at the approved dose in combination with fulvestrant: 300 mg taken PO QD and on days 1-28 of each 28-day cycle.
Study: NCT06629220

Intervention type: OTHER
Group type: OTHER
Intervention: Tools
Description: In the co-creation meetings, developed tools will be presented. Participants will be asked to provide feedback and input to tailor these tools to the needs and preferences of men with suicidal thoughts/behavior.
Study: NCT05053321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: All participants will be treated with Valbenazine for 6 weeks.
Study: NCT06628622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356225
Description: BI 1356225

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04472351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASCEND-I
Description: The intervention is an inpatient version of a novel behavioral intervention named ASCEND (A Strategy and Computer-based Intervention to ENhance Daily Cognitive Functioning after Stroke). ASCEND-I combines computer-based cognitive training exercises, with structured coaching sessions within patients' occupational therapy. Computer-based training is 30 minutes in length daily, and strategy training within patients' occupational therapy ranges from 30-60 minutes (depending on patients' clinical goals). The computer exercises aim to improve working memory (WM) through a series of engaging and interactive computer games (e.g., card games, virtual shopping, mental arithmetic). The Multicontext OT sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to everyday activities and to develop further strategies to compensate for WM difficulties.
Study: NCT06098183

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Whey Protein Isolate
Description: Whey protein isolate essential amino acids (25 g), 5.5 grams of branched-chain amino acids (BCAAs), and 2.7 grams of Leucine per serving

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate
Description: Whey protein isolate essential amino acids (25 g), 5.5 grams of branched-chain amino acids (BCAAs), and 2.7 grams of Leucine per serving

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-caloric Placebo water
Description: Non-caloric placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-caloric Placebo water
Description: Non-caloric placebo
Study: NCT04524247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physician Modified Endografts
Description: Modification procedure Description of modified device is detailed in Section 3.5 of IDE. In summary, the steps involved in modification of the Zenith Alpha thoracic stent grafts are;~1. Unsheathing of the stent graft~2. Retrieval of a trigger wire from the inner cannula of the delivery system~3. Rerouting of the trigger wire along the stent graft~4. Removal of proximal barbs.~5. Creation of fenestrations and/or branch cuffs~6. Placement of radiopaque markers around the fenestrations/ branch cuffs~7. Placement of temporary and/or permanent diameter constraining ties~8. (Optional) Placement of preloaded wires through the fenestrations/branch cuffs
Study: NCT05379218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Description: Patients randomized to the RIC arm, cohorts of 4 consecutive patients will receive escalating therapy:~A. 4 consecutive patients will undergo 4 cycles of 3 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia B. Observing no safety events (see below) from patients in group A, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia.~C. Observing no safety events from patients in group B, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1 and 2 of therapeutic hypothermia.~D. Observing no safety events from patients in group C, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1, 2, and 3 of therapeutic hypothermia.~All infants will have an extra 1ml of blood collected.
Study: NCT05566691

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive thinking
Description: Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts.
Study: NCT05607199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR103
Description: Twice Daily
Study: NCT06294756

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation of Sulfurous Thermal Water
Description: Active Inhalation protocol based on 12 consecutive sessions, 20 minutes each, once a day from Visit 1 through a conventional thermal water aerosolization Faset™system (Faset Spa, Trezzano sul Naviglio, Milan, Italy) delivering particles of TW with a diameter between 0.6 µm \<MMAD \< 5 µm. Treatment consisted of 10 minutes of warm steam and 10 minutes of aerosol inhalation with nasal prongs.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inhalation of Sterile Distilled non-pyrogenic Water
Description: Placebo Inhalation protocol based on 12 consecutive sessions, 20 minutes each, once a day from Visit 1 through a modified thermal water aerosolization Faset™system, previously disconnected from the hydraulic circuit that supplied TW and connected to non-pyrogenic sterile water reservoirs (Highly depurated water- Pharmaceutical grade FU-for external and internal use, Makeitlab, Canosa di Puglia, BT, Italy). Treatment consisted of 10 minutes of warm steam and 10 minutes of aerosol inhalation with nasal prongs delivering particles of SDW with a diameter between 0.6 µm \<MMAD \< 5 µm.
Study: NCT05566691

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive thinking + Mood induction
Description: Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thought reevaluation
Description: Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thought reevaluation + Mood induction
Description: Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
Study: NCT04597359

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT04798924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subacute Training in the intact field
Description: A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the intact field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subacute Training in the blind field
Description: A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chronic Training in the blind field
Description: After the initial training period of one to six months, the same computer software will continue to be used for all subjects. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chronic Training in the blind field
Description: After the initial training period of one to six months, the same computer software will continue to be used for all subjects. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 6 months.
Study: NCT05650632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-383
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-383
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-383
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-383
Description: Intravenous Infusion
Study: NCT05693129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leniolisib
Description: The doses selected will range from 10 to 50 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 100 mg per day).
Study: NCT06051032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon thrombectomy
Description: A specialized catheter with an inflatable balloon at the tip is inserted over a guidewire, previously inserted through the sheath, and advanced to the location of the clot within the blood vessel. The catheter is positioned precisely using fluoroscopic guidance or other imaging modalities. Once positioned, the balloon is inflated, creating pressure against the clot and effectively removing or dislodging it from the vessel walls.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thromboaspiration system
Description: The thromboaspiration catheter is carefully guided to the site of the clot within the blood vessel. Once positioned, the suction mechanism is activated, creating a vacuum effect. The catheter gently aspirates or suctions the clot, gradually removing it from the vessel walls. The procedure is performed under fluoroscopic guidance or other imaging modalities to ensure accurate placement of the catheter and successful clot aspiration.
Study: NCT06034496

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active CES
Description: Active CES group will receive a minimum of 250µA and up to 500µA depending on thresholding, once daily for 20 days (over the course of 4\~6 weeks), 20 minutes per day.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CES
Description: Sham CES group will be identical to Active CES group with the exception of the device not administering any electrical current
Study: NCT06365437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCD601
Description: Investigational Product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCD601
Description: Investigational Product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCD601
Description: Investigational Product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCD601
Description: Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (TAC)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids (CS)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Description: Standard of Care Concomitant Immunosuppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: Standard of Care induction therapy in solid organ transplantation
Study: NCT05563857

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: VIOME Precision Nutrition Program
Description: Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VIOME-designed condition-based supplements
Description: Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
Study: NCT06348849

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level laser therapy
Description: Wavelength 980nm (SmartM, Lasotronix, Poland)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanosilver fluoride
Description: Optimized synthesis of Nanosilver Fluoride
Study: NCT06334952

Intervention type: DEVICE
Group type: OTHER
Intervention: transcranial direct current stimulation
Description: Research MRI includes 3D-T1 weighted MRI (3D-T1), diffusion MRI (dMRI), resting-state functional MRI (rsfMRI).

Intervention type: DEVICE
Group type: OTHER
Intervention: transcranial direct current stimulation
Description: Research MRI includes 3D-T1 weighted MRI (3D-T1), diffusion MRI (dMRI), resting-state functional MRI (rsfMRI).
Study: NCT05531643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Cefaly Dual (R)
Description: Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A biphasic rectangular wave will be delivered for a maximum of 20 minutes at a maximum amplitude of 16mA. Participant may halt amplitude before it reaches maximum amplitude. The device has previously been cleared by the FDA for use in migraine patients.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Cefaly Dual (R)
Description: Transcutaneous electrical nerve stimulation (TENS) device with electrode placement at the forehead. A 1Hz wave will be delivered for 20 minutes at 1mA.
Study: NCT06377566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin will be administered at 1.2 mg/kg IV on days 1 and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 25 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine 6 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine 375 mg/m\^2 IV on days 1 and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at 200 mg IV (flat) on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 IV (days 1 an

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinblastine 6 mg/m\^2 IV

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT scan
Description: After 2 cycles of therapy, patients will undergo FDG-PET/CT scan
Study: NCT04651088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium citrate
Description: Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium citrate
Description: Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Potassium citrate
Description: Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium citrate
Description: Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium citrate
Description: Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium citrate
Description: Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: 650mg tabs. Take 3 tabs twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: 650mg tabs. Take 3 tabs twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium bicarbonate
Description: 650mg tabs. Take 3 tabs twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: 650mg tabs. Take 3 tabs twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: 650mg tabs. Take 3 tabs twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: 650mg tabs. Take 3 tabs twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Litholyte
Description: One packet is taken with 170ml of water. Two packets daily.
Study: NCT04597359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04651088

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Litholyte
Description: One packet is taken with 170ml of water. Two packets daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Litholyte
Description: One packet is taken with 170ml of water. Two packets daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Litholyte
Description: One packet is taken with 170ml of water. Two packets daily.
Study: NCT04597359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinecatechins
Description: Given PO
Study: NCT05045807

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat with added nitrate
Description: Prosciutto/pancetta/Parma ham/salami (all derived from pork) prepared by a commercial butcher with the sodium nitrate and nitrite as an additive.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat with added nitrate plus vegetables
Description: The same intervention as of intervention meat with added nitrate consumed together with mixed vegetables.
Study: NCT05053334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab Prefilled Syringe
Description: 150mg/ml of Omalizumab prefilled syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab Prefilled Syringe
Description: 150mg/ml of Omalizumab prefilled syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab Prefilled Syringe
Description: 150mg/ml of Omalizumab prefilled syringe
Study: NCT05456464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki is applied touching the energy centers of the body (chakras). There are seven main and many small chakras on a body. Chakras are located on the front and back sides of the body in a vertical line that runs along the middle of the body in humans. A complete Reiki therapy includes all the chakras and organs.